Diagnostics

Primary care digital screening tool for Alzheimer’s disease

Clinical robustness of CSF pTau/Aβ42 ratio for Alzheimer’s disease diagnosis

Mild behavioral impairment is associated with abnormal AD CSF biomarker profiles in MCI

Prioritizing the mechanistic understanding of AD to improve treatments

Longitudinal clinical outcomes of tau-PET-positive individuals

Clinical implementations of AlzoSure Predict

Predicting tau-PET signal in early Alzheimer’s disease using speech biomarkers

Blood-based biomarkers as surrogates of amyloid burden in preclinical Alzheimer’s disease

Limitations of [18F]flortaucipir tau-PET imaging

Speech biomarker for cognition: a novel marker for AD clinical trial screening

Identifying dementia with Lewy bodies in the presence of Alzheimer’s disease

Performance of plasma p-tau181 as a community-based screening tool for AD clinical trials

The diagnostic and prognostic performance of U-p53AZ as a blood-based biomarker for AD

The value of plasma p-tau181 as a screening and diagnostic tool for Alzheimer’s disease

Understanding the effect of other diseases on blood biomarker levels in AD

Screening for delirium in individuals with dementia